Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | DTYMK | P23919 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.43 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14667939 | 0.84 | ALDH1A1 (0.50) | GPR35ALDH1A1LMNAKDM4ECYP3A4 | |
| SCHEMBL7055312 | 0.84 | GPR35 (0.54) | GPR35ALDH1A1LMNAKDM4EGLA | |
| SCHEMBL3888136 | 0.82 | ALDH1A1 (0.75) | GPR35ALDH1A1LMNAKDM4ECYP3A4 | |
| SCHEMBL21749931 | 0.82 | GPR35 (0.52) | GPR35LMNAKDM4EGLATDP1 | |
| SCHEMBL1446831 | 0.82 | AKR1C2 (0.56) | GPR35ALDH1A1KDM4EALOX15TDP1 | |
| SCHEMBL2591086 | 0.81 | TSHR (0.56) | GPR35ALDH1A1TDP1DTYMKERN1 | |
| SCHEMBL9086480 | 0.81 | GPR35 (0.51) | GPR35ALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL505297 | 0.81 | KDM4E (0.58) | GPR35ALDH1A1LMNAKDM4ECYP3A4 | |
| SCHEMBL505380 | 0.81 | ALDH1A1 (0.50) | ALDH1A1LMNACYP3A4ALOX15TDP1 | |
| SCHEMBL18342840 | 0.81 | GPR35 (0.51) | GPR35ALDH1A1LMNAKDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3585772-B1 | 1, 4, 6-TRISUBSTITUTED-2-ALKYL-1H-BENZO[D]IMIDAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | MERCK PATENT GMBH (DE) | 2023-10-11 | — | — | EP | disclosed |
| CN-110325514-B | 1,4, 6-trisubstituted-2-alkyl-1H-benzo [ d ] imidazole derivatives as dihydroorotate oxygenase inhibitors | 默克专利有限责任公司 | 2023-06-13 | — | — | CN | disclosed |
| US-11028054-B2 | 1, 4, 6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors | MERCK PATENT GMBH (DE) | 2021-06-08 | — | — | US | disclosed |
| US-11028054-B2 | 1, 4, 6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors | MERCK PATENT GMBH (DE) | 2021-06-08 | — | — | US | disclosed |
| US-20200140395-A1 | 1, 4, 6-TRISUBSTITUTED-2-ALKYL-1H-BENZO[D]IMIDAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | MERCK PATENT GMBH (DE) | 2020-05-07 | — | — | US | disclosed |
| US-20200140395-A1 | 1, 4, 6-TRISUBSTITUTED-2-ALKYL-1H-BENZO[D]IMIDAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | MERCK PATENT GMBH (DE) | 2020-05-07 | — | — | US | disclosed |
| WO-2018154088-A1 | 1, 4, 6-TRISUBSTITUTED-2-ALKYL-1H-BENZO[D]IMIDAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | MERCK PATENT GMBH (DE) | 2018-08-30 | — | — | WO | disclosed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| US-9932324-B2 | Substituted benzimidazolium compounds useful in the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-04-03 | — | — | US | disclosed |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| WO-2010115736-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115736-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
| CN-1128797-C | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivs. substd. with N- or C-linked imidazoles | JANSSEN PHARMACEUTICA NV (BE) | 2003-11-26 | — | — | CN | disclosed |
| EP-0970079-B1 | FARNESYL TRANSFERASE INHIBITING 1,8-ANNELATED QUINOLINONE DERIVATIVES SUBSTITUTED WITH N- OR C-LINKED IMIDAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2003-10-01 | — | — | EP | disclosed |
| US-6444812-B1 | SUCH AS 7-(3-CHLOROPHENYL)-9-((4-CHLOROPHENYL)-1H-IMIDAZOL-1-YLMETHYL)-2,3-DIHYDRO -1H,5H-BENZO(IJ) QUINOLIZIN-5-ONE; FOR FORMING ONCOGENES FOR SIGNALLING TRANSFORMATION OF TUMOR CELLS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-09-03 | — | — | US | disclosed |
| US-20020049327-A1 | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles | VENET MARC GASTON (FR) | 2002-04-25 | — | — | US | disclosed |
| US-6187786-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-02-13 | — | — | US | disclosed |
| EP-0970079-A1 | FARNESYL TRANSFERASE INHIBITING 1,8-ANNELATED QUINOLINONE DERIVATIVES SUBSTITUTED WITH N- OR C-LINKED IMIDAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998040383-A1 | FARNESYL TRANSFERASE INHIBITING 1,8-ANNELATED QUINOLINONE DERIVATIVES SUBSTITUTED WITH N- OR C-LINKED IMIDAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140395-A1 | 1, 4, 6-TRISUBSTITUTED-2-ALKYL-1H-BENZO[D]IMIDAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | DHODH, HAAO, OGDH | GPR35 1877/4885ALDH1A1 92/4885LMNA 4321/4885 |
| US-11028054-B2 | 1, 4, 6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors | DHODH, HAAO, OGDH | GPR35 1877/4885ALDH1A1 92/4885LMNA 4321/4885 |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, FH, DPYD | GPR35 4023/4885ALDH1A1 95/4885LMNA 4317/4885 |
| US-20020049327-A1 | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles | HCCS, CYP7A1, DHCR7 | GPR35 2795/4885ALDH1A1 533/4885LMNA 2864/4885 |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | BRCA1, NQO2, NQO1 | GPR35 3868/4885ALDH1A1 1674/4885LMNA 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.